Hypertension. A Companion to Braunwald's Heart Disease. Edition No. 4

Table of Contents

SECTION I: EPIDEMIOLOGY AND PREVENTIVE STRATEGIES
1. General Population and Global Cardiovascular Risk Prediction
2. Diet and Hypertension
3. Exercise and Hypertension
4. Hypertension in Women
SECTION II: PATHOPHYSIOLOGY
5. Pathophysiology of Hypertension
6. Genetics of Hypertension
7. Inflammation and Immunity in Hypertension
SECTION III: DIAGNOSIS AND EVALUATION
8. The Environment and High Blood Pressure
9. Office Blood Pressure Measurement
10. Home Monitoring of Blood Pressure
11. Ambulatory Blood Pressure Monitoring in Clinical Hypertension Management
12. White Coat and Masked Hypertension
13. Renovascular Hypertension and ISchemic Neuropathy
14. Secondary Hypertension: Primary Hyperaldosteronism and Mineralocorticoid Excess States
15. Secondary Hypertension: Pheochromocytoma and Paraganglioma
16. Sleep Disruption and Blood Pressure
SECTION IV: RISK STRATIFICATION
17. The Natural History of Untreated Hypertension
18. Isolated Systolic Hypertension
19. Assessment of Hypertension-Mediated Organ Damage
SECTION V: ANTIHYPERTENSIVE THERAPY
20. Diuretics Therapy
21. Calcium Channel Blockers
22. Renin Angiotensin Aldosterone System Blockers
23. Aldosterone and Hypertension
24. �-Blockers, Central Sympathetic Agents,and Direct Vasodilators
25. Peripheral Alpha Blockers
26. Initial Combination Therapies
27. Devices Therapies for Hypertension
28. The Treatment of Hypertension With Nutrition, Nutritional Supplements, and Lifestyle
SECTION VI: HYPERTENSION MANAGEMENT APPROACHES
29. Approach to Difficult to Manage Primary Hypertension
30. Team-Based Care for Hypertension Management
31. Medication Adherence: Focus on Improvement
32. Digital Health and Telemedicine for Hypertension
SECTION VII HYPERTENSION MANAGEMENT WITH COMORBIDITIES
33. Ischemic Heart Disease
34. Heart Failure
35. Hypertension and Chronic Kidney Disease Including Dialysis
36. Transplant Hypertension
37. Obesity and Hypertension: Pathophysiology and Treatment
38. Cerebrovascular Disease
39. Diabetes Mellitus: Management of Hypertension in Diabetes
40. Onco-Hypertension: Anticancer Therapy-Associated Hypertension
41. Autonomic Dysfunction and Orthostatic Hypotension
42. Dyslipidemia
43. Aorta and Peripheral Arterial Disease in Hypertension
SECTION VIII SPECIAL POPULATIONS
44. Hypertension in Pregnancy
45. Hypertension in Older People
46. Hypertension in African Americans
47. Resistant Hypertension
48. Hypertensive Emergencies and Urgencies
49. Hypertension in Children: Diagnosis and Treatment
Appendix Meta-Analyses of Blood Pressure Lowering Trials
Index

Authors

George L. Bakris Professor of Medicine, Director, Comprehensive Hypertension Center, University of Chicago Medicine, Chicago, Illinois. George L Bakris, MD, is a nephrologist whose specialty is kidney function/disease and hypertension. He has led several large NIH-funded studies resulting in paradigm shifts in blood pressure treatment guidelines for patients with treatable and challenging hypertension. Dr Bakris is Professor of Medicine and Director of the American Heart Association Comprehensive Hypertension Center at the University of Chicago in Chicago, Illinois. Matthew Sorrentino Professor of Medicine, Associate Director, Bucksbaum Institute for Clinical Excellence, University of Chicago Medicine, Chicago, Illinois. Matthew J Sorrentino, MD, a cardiologist whose focus is preventive cardiology, is Professor of Medicine at the Bucksbaum Institute for Clinical Excellence and Vice Chair of Clinical Operations for the Department of Medicine at the University of Chicago. Both Drs Bakris and Sorrentino edited the current edition of Hypertension. Luke J. Laffin Co-Director, Center for Blood Pressure Disorders, Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio. Luke J Laffin, MD, is Co-Director of the Center for Blood Pressure Disorders in the Department of Cardiovascular Medicine at Cleveland Clinic in Cleveland, Ohio. Dr Laffin was a contributor on the current edition.